In the global biopharmaceutical industry, protein-based therapies are effectively being used to treat metabolic disorders, and autoimmune diseases. According to our new research report, the global market for insulin products is progressing on the strong growth trajectory as the number of people suffering from diabetes is increasing at a rapid rate worldwide. It is estimated that the market will advance at a CAGR of around 10% during 2012-2015.
The report, “Insulin Market Forecast to 2015”, says that new innovations in delivery devices are also likely to fuel growth in the global insulin market. In the recent years, many alternatives to insulin syringes have been launched, including pen devices, and insulin pumps. Our comprehensive research work also studies how government initiatives are stimulating the growth, and what are the challenges that the overall market may face in near future.
Our extensive study looks into the competitive landscape and finds that Novo Nordisk is the top player in the global insulin market, followed by Sanofi-Aventis and Eli Lilly. The report includes an overview of the activities of these companies. It also studies key geographies, such as BRIC nations and the United States to understand the structure of the insulin market in these countries. Overall, the research aims at presenting a balanced picture of the global insulin market to clients.
